glp-1 drugs manufacturers suppliers distributors 2023-2025 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 Drug Channels Institute | The

Available from: Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D et al (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

While many patients experience benefits from taking GLP-1s, there are some fairly significant side effects associated with these medications

Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you

Researchers observed that while GLP-1s offer overall kidney protective benefits, SGLT2 inhibitors appear to be more effective at slowing the progression to end-stage kidney failure

These numbers should be interpreted cautiously given the different trial designs, but the trend is consistent across multiple analyses